LDT Appeal: Looking at the Legal Nuances Behind Potential FDA Actions Following Court Decision
Marginal LDT scenarios could be where the FDA focuses on next, a lawyer notes
Marginal LDT scenarios could be where the FDA focuses on next, a lawyer notes
The court recently denied the petition to hear a case that would have helped offer clarity on what evidence whistleblowers need to file qui tam lawsuits under the FCA.
After the DOJ announced a massive National Health Care Fraud Enforcement Action on July 20 targeting telehealth and telemarketing scams, labs need to be extremely wary, especially if they provide genetic testing.
While the report’s most significant findings involved labs and lab testing, it wasn’t just the usual finger pointing this time.
If your lab received federal relief funds from the US government during the COVID-19 pandemic, you could be at risk of FCA lawsuits.
UDT false billing cases seem to be on the rise again, accounting for a trio of recent multimillion dollar settlements.
MFCU enforcement activity has rebounded from recent declines but still hasn’t reached pre-pandemic levels, according to a recent OIG report.
Thanks to recent federal enforcement initiatives, prompt response to patient PHI requests should be a growing priority for HIPAA compliance.
This month’s roundup includes the continued court battle between BGI and Illumina, an FCA lawsuit, and the latest version of OSHA’s COVID-19 rule.
What happens when a whistleblower’s case is based on information that’s already been publicly disclosed?
The cost of recoveries hit an eight-year high in FY 2021, with the health care industry footing 90 percent of the bill.